Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 147

1.

Prognostic and predictive value of circulating tumor cell analysis in colorectal cancer patients.

de Albuquerque A, Kubisch I, Stölzel U, Ernst D, Boese-Landgraf J, Breier G, Stamminger G, Fersis N, Kaul S.

J Transl Med. 2012 Nov 13;10:222. doi: 10.1186/1479-5876-10-222.

2.

Multimarker gene analysis of circulating tumor cells in pancreatic cancer patients: a feasibility study.

de Albuquerque A, Kubisch I, Breier G, Stamminger G, Fersis N, Eichler A, Kaul S, Stölzel U.

Oncology. 2012;82(1):3-10. doi: 10.1159/000335479. Epub 2012 Jan 20.

PMID:
22270149
3.

Prognostic Role of a Multimarker Analysis of Circulating Tumor Cells in Advanced Gastric and Gastroesophageal Adenocarcinomas.

Kubisch I, de Albuquerque A, Schuppan D, Kaul S, Schaich M, Stölzel U.

Oncology. 2015;89(5):294-303. doi: 10.1159/000437373. Epub 2015 Aug 28.

PMID:
26315108
4.

A multimarker panel for circulating tumor cells detection predicts patient outcome and therapy response in metastatic colorectal cancer.

Barbazán J, Muinelo-Romay L, Vieito M, Candamio S, Díaz-López A, Cano A, Gómez-Tato A, Casares de Cal Mde L, Abal M, López-López R.

Int J Cancer. 2014 Dec 1;135(11):2633-43. doi: 10.1002/ijc.28910. Epub 2014 Apr 29.

5.

Cytokeratin-20 and Survivin-Expressing Circulating Tumor Cells Predict Survival in Metastatic Colorectal Cancer Patients by a Combined Immunomagnetic qRT-PCR Approach.

Ning Y, Hanna DL, Zhang W, Mendez A, Yang D, El-Khoueiry R, Matsusaka S, Sunakawa Y, Stremitzer S, Parekh A, Okazaki S, Berger MD, Barzi A, Lenz HJ.

Mol Cancer Ther. 2015 Oct;14(10):2401-8. doi: 10.1158/1535-7163.MCT-15-0359. Epub 2015 Jul 30.

6.

Relationship between circulating tumor cells and tumor response in colorectal cancer patients treated with chemotherapy: a meta-analysis.

Huang X, Gao P, Song Y, Sun J, Chen X, Zhao J, Liu J, Xu H, Wang Z.

BMC Cancer. 2014 Dec 18;14:976. doi: 10.1186/1471-2407-14-976.

7.

Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish Cooperative Group for the Treatment of Digestive Tumors study.

Sastre J, Maestro ML, Gómez-España A, Rivera F, Valladares M, Massuti B, Benavides M, Gallén M, Marcuello E, Abad A, Arrivi A, Fernández-Martos C, González E, Tabernero JM, Vidaurreta M, Aranda E, Díaz-Rubio E.

Oncologist. 2012;17(7):947-55. doi: 10.1634/theoncologist.2012-0048. Epub 2012 May 29.

8.

Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, RAS-BRAF wild-type colorectal cancer receiving cetuximab or panitumumab.

Musella V, Pietrantonio F, Di Buduo E, Iacovelli R, Martinetti A, Sottotetti E, Bossi I, Maggi C, Di Bartolomeo M, de Braud F, Daidone MG, Cappelletti V.

Int J Cancer. 2015 Sep 15;137(6):1467-74. doi: 10.1002/ijc.29493. Epub 2015 Mar 4.

9.

Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer.

Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse M, Mitchell E, Miller MC, Doyle GV, Tissing H, Terstappen LW, Meropol NJ.

J Clin Oncol. 2008 Jul 1;26(19):3213-21. doi: 10.1200/JCO.2007.15.8923. Erratum in: J Clin Oncol. 2009 Apr 10;27(11):1923.

PMID:
18591556
10.

Detection of circulating tumor cells with CK20 RT-PCR is an independent negative prognostic marker in colon cancer patients - a prospective study.

Hinz S, Hendricks A, Wittig A, Schafmayer C, Tepel J, Kalthoff H, Becker T, Röder C.

BMC Cancer. 2017 Jan 13;17(1):53. doi: 10.1186/s12885-016-3035-1.

11.

Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer.

Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse MA, Mitchell E, Miller MC, Doyle GV, Tissing H, Terstappen LW, Meropol NJ.

Ann Oncol. 2009 Jul;20(7):1223-9. doi: 10.1093/annonc/mdn786. Epub 2009 Mar 12.

PMID:
19282466
12.

The role of circulating tumor cells in evaluation of prognosis and treatment response in advanced non-small-cell lung cancer.

Zhou J, Dong F, Cui F, Xu R, Tang X.

Cancer Chemother Pharmacol. 2017 Apr;79(4):825-833. doi: 10.1007/s00280-017-3269-x. Epub 2017 Mar 13.

PMID:
28289866
13.

Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer.

Liu MC, Shields PG, Warren RD, Cohen P, Wilkinson M, Ottaviano YL, Rao SB, Eng-Wong J, Seillier-Moiseiwitsch F, Noone AM, Isaacs C.

J Clin Oncol. 2009 Nov 1;27(31):5153-9. doi: 10.1200/JCO.2008.20.6664. Epub 2009 Sep 14.

14.

Circulating tumor cells in metastatic colorectal cancer: do we need an alternative cutoff?

Gazzaniga P, Raimondi C, Gradilone A, Biondi Zoccai G, Nicolazzo C, Gandini O, Longo F, Tomao S, Lo Russo G, Seminara P, Vincenzi B, Chimenti I, Cristofanilli M, Frati L, Cortesi E.

J Cancer Res Clin Oncol. 2013 Aug;139(8):1411-6. doi: 10.1007/s00432-013-1450-0. Epub 2013 Jun 5.

PMID:
23736274
15.

Prognostic value of the combination of circulating tumor cells plus KRAS in patients with metastatic colorectal cancer treated with chemotherapy plus bevacizumab.

Sastre J, Vidaurreta M, Gómez A, Rivera F, Massutí B, López MR, Abad A, Gallen M, Benavides M, Aranda E, Rubio ED; Spanish Cooperative Group for the Treatment of Digestive Tumors.

Clin Colorectal Cancer. 2013 Dec;12(4):280-6. doi: 10.1016/j.clcc.2013.06.001. Epub 2013 Sep 5.

PMID:
24012456
16.

Combination of circulating tumor cell enumeration and tumor marker detection in predicting prognosis and treatment effect in metastatic castration-resistant prostate cancer.

Chang K, Kong YY, Dai B, Ye DW, Qu YY, Wang Y, Jia ZW, Li GX.

Oncotarget. 2015 Dec 8;6(39):41825-36. doi: 10.18632/oncotarget.6167.

17.

Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment.

Giuliano M, Giordano A, Jackson S, Hess KR, De Giorgi U, Mego M, Handy BC, Ueno NT, Alvarez RH, De Laurentiis M, De Placido S, Valero V, Hortobagyi GN, Reuben JM, Cristofanilli M.

Breast Cancer Res. 2011 Jun 15;13(3):R67. doi: 10.1186/bcr2907.

18.

Heterogeneous detection of circulating tumor cells in patients with colorectal cancer by immunomagnetic enrichment using different EpCAM-specific antibodies.

Antolovic D, Galindo L, Carstens A, Rahbari N, Büchler MW, Weitz J, Koch M.

BMC Biotechnol. 2010 Apr 28;10:35. doi: 10.1186/1472-6750-10-35.

19.

Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer.

Mu Z, Wang C, Ye Z, Austin L, Civan J, Hyslop T, Palazzo JP, Jaslow R, Li B, Myers RE, Jiang J, Xing J, Yang H, Cristofanilli M.

Breast Cancer Res Treat. 2015 Dec;154(3):563-71. doi: 10.1007/s10549-015-3636-4. Epub 2015 Nov 16.

PMID:
26573830
20.

Circulating tumor cells count predicts survival in colorectal cancer patients.

Romiti A, Raffa S, Di Rocco R, Roberto M, Milano A, Zullo A, Leone L, Ranieri D, Mazzetta F, Medda E, Sarcina I, Barucca V, D'Antonio C, Durante V, Ferri M, Torrisi MR, Marchetti P.

J Gastrointestin Liver Dis. 2014 Sep;23(3):279-84. doi: 10.15403/jgld.2014.1121.233.arom1.

Supplemental Content

Support Center